|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-1-4
|
|
pubmed:abstractText |
After two decades of interferon (IFN) treatment in myeloma patients and many randomised clinical trials, no definite proof of its benefits exists. This meta-analysis of all available relevant published data tests the differences between IFN and control arms in a large patient population and addresses the issue of cost-effectiveness.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1427-36
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11142483-Cost-Benefit Analysis,
pubmed-meshheading:11142483-Disease-Free Survival,
pubmed-meshheading:11142483-Drug Costs,
pubmed-meshheading:11142483-Humans,
pubmed-meshheading:11142483-Immunologic Factors,
pubmed-meshheading:11142483-Interferon-alpha,
pubmed-meshheading:11142483-Life Tables,
pubmed-meshheading:11142483-Multiple Myeloma,
pubmed-meshheading:11142483-Randomized Controlled Trials as Topic,
pubmed-meshheading:11142483-Survival Analysis,
pubmed-meshheading:11142483-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.
|
|
pubmed:affiliation |
First Department of Medicine and Oncology, Wilhelminenspital, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
